Articles related to DRUG SAFETY & INTERACTIONS

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

University of Oklahoma researchers identified a photoreceptor lysosomal recycling pathway regulated by PIKfyve. Mouse-model disruption produced photoreceptor degeneration and RPE changes resembling macular degeneration biology.

Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.

The FDA issued a Class II recall for an amphetamine-based ADHD medication after a labeling mix-up resulted in immediate-release capsules being packaged as extended release. The recall affects a single lot totaling 1,392 bottles.

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.